The CD4-gp120 interaction and AIDS pathogenesis. NLM AIDSLINE Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


The CD4-gp120 interaction and AIDS pathogenesis.

Annu Rev Immunol. 1991;9:649-78. Unique Identifier : AIDSLINE MED/92000518
Capon DJ; Ward RH; Genentech Inc., South San Francisco, California 94080.

Abstract: Infection by the human immunodeficiency virus (HIV) leads to progressive destruction of the CD4+ subset of T lymphocytes, resulting in immunodeficiency and AIDS. The selectivity of CD4+ cell destruction is due to the specific binding of gp120, the external envelope glycoprotein of HIV, to CD4, initiating viral entry. Binding of gp120 to CD4 on the cell surface may also lead to CD4+ cell depletion by inappropriate immune targeting, and may interfere with CD4+ cell function and ontogeny by disrupting CD4-mediated cell signaling. The CD4-gp120 interaction is thus an obvious target for AIDS therapeutics.
Keywords: Acquired Immunodeficiency Syndrome/*ETIOLOGY/THERAPY Amino Acid Sequence Antigens, CD4/*METABOLISM Attachment Sites (Microbiology) Binding Sites Cell Fusion Human HIV Envelope Protein gp120/CHEMISTRY/*METABOLISM Molecular Sequence Data Protein Binding JOURNAL ARTICLE REVIEW REVIEW, ACADEMIC

KWDacquiredimmunodeficiencysyndrome/KWDetiology/therapyaminoacidsequenceantigens,cd4/KWDmetabolismattachmentsites(microbiology)bindingsitescellfusionhumanhivenvelopeproteingp120/chemistry/KWDmetabolismmolecularsequencedataproteinbindingjournalarticlereviewreview,academic
920130
M9210740

Copyright © 1992 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .